Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient [2]

Bone Marrow Transplantation

Volumn 39, Issue 10, 2007, Pages 649-651

  Ostronoff, M ^a   Ostronoff, F ^a   Calixto, R ^a   Florencio R ^a   Florencio M ^a   Domingues, M C ^a   Souto Maior, A P ^a   Sucupira, A ^a   Tagliari, C ^a  

^a Real Hospital Portugues   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FRESH FROZEN PLASMA; HEMOGLOBIN; LACTATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; UREA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ARTIFICIAL VENTILATION; CANCER REGRESSION; CASE REPORT; CONSENSUS; DISEASE SEVERITY; DRUG WITHDRAWAL; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FATALITY; FATIGUE; GINGIVA BLEEDING; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEMATURIA; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG EDEMA; LYMPHADENOPATHY; MALE; NAUSEA; NEUTROPHIL; PLASMA VOLUME; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; SIBLING; TESTIS CANCER; THROMBOCYTE COUNT; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; TRANSPLANTATION, HOMOLOGOUS;

EID: 34248173530     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705657     Document Type: Letter

References (16)

1. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: A diagnostic dilemma. Transfusion 2004; 44 294-304.
2. Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005; 84: 232-235.
3. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005; 106: 1932-1937.
4. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451-461.
5. Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005; 19: 423-426.
6. Brandalise S, Odone V, Pereira W, Andrea M, Zanichelli M, Aranega V. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group. Leukemia 1993; 7(Suppl 2): S142-S145.
7. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504.
8. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: A case series. Bone Marrow Transplant 1995; 15: 247-253.
9. Iacopino P, Pucci G, Arcese W, Bosi A, Falda M, Locatelli F et al. Severe thrombotic microangiopathy: An infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999; 24: 47-51.
10. Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: A survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112-1119.
11. Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113: 58-64.
12. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571.
13. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
14. Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 2005; 12: 359-363.
15. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-3802.
16. Natazuka T, Kajimoto K, Ogawa R, Imoto S, Koizumi T, Nishimura R et al. Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies. Bone Marrow Transplant 1998; 21: 815-819.